Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01190449 · ClinicalTrials.gov registry record · Phase 2
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
A Phase 2 study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 20
- Study locations
NCT01190449 is a Phase 2 study of Lymphoma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 51 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT01190449, a Phase 2 study of Lymphoma, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Monoclonal antibodies, such as ofatumumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. PURPOSE: This randomized phase II trial is studying ofatumumab to see how well it works in treating patients with previously untreated stage II, stage III, or stage IV follicular non-Hodgkin lymphoma.
Conditions Studied
Interventions
- BIOLOGICAL ofatumumab
Study Locations (20)
Illinois
- Illinois CancerCare - Bloomington - Bloomington
- Illinois CancerCare - Canton - Canton
- Eureka Community Hospital - Eureka
- Illinois CancerCare - Eureka - Eureka
- Galesburg Clinic, PC - Galesburg
- Illinois CancerCare - Macomb - Macomb
- BroMenn Regional Medical Center - Normal
- Community Cancer Center - Normal
- Illinois CancerCare - Community Cancer Center - Normal
- Community Hospital of Ottawa - Ottawa
- Oncology Hematology Associates of Central Illinois, PC - Ottawa - Ottawa
- Cancer Treatment Center at Pekin Hospital - Pekin
- Illinois CancerCare - Pekin - Pekin
- Proctor Hospital - Peoria
- CCOP - Illinois Oncology Research Association - Peoria
- Oncology Hematology Associates of Central Illinois, PC - Peoria - Peoria
- Methodist Medical Center of Illinois - Peoria
Delaware
- Tunnell Cancer Center at Beebe Medical Center - Lewes
- CCOP - Christiana Care Health Services - Newark
Florida
- Cleveland Clinic Florida - Weston - Weston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2011-08 |
| Est. Completion | 2020-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01190449
The ClinicalTrials.gov registry entry for NCT01190449 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (89% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which ofatumumab is the first listed.
NCT01190449 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Delaware, Florida.
Frequently Asked Questions
What is clinical trial NCT01190449 about?
NCT01190449 is a clinical study titled "Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma". RATIONALE: Monoclonal antibodies, such as ofatumumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. PURPOSE: This randomized phase II trial is studying ofa...
What is the current status of trial NCT01190449?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2011-08. Estimated completion is 2020-10-15.
What conditions does trial NCT01190449 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT01190449?
The interventions under investigation include: ofatumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01190449?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01190449 being conducted?
This trial has 20 study locations across Delaware, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.